French Luxury Stock News

ENXTPA:DSY
ENXTPA:DSYSoftware

Why Dassault Systèmes (ENXTPA:DSY) Is Up 6.4% After CEO Pascal Daloz Assumes Chairmanship And What's Next

On February 21, 2026, Dassault Systèmes announced that long‑time leader Bernard Charlès stepped down as Executive Chairman and Board member for personal reasons, with CEO Pascal Daloz immediately assuming the combined role of Chairman and Chief Executive Officer. This rapid consolidation of leadership under Daloz marks a significant governance shift for a company long shaped by its co‑founder’s vision, raising fresh questions about how its innovation culture and AI‑driven 3D virtual universe...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Sanofi (ENXTPA:SAN) Valuation Check After New EMA Support For Dupixent And Acoziborole

Sanofi (ENXTPA:SAN) is back in focus after two fresh positive opinions from Europe’s medicines regulator on Dupixent for pediatric chronic spontaneous urticaria and Acoziborole Winthrop for sleeping sickness, spotlighting its late stage specialty portfolio. See our latest analysis for Sanofi. Sanofi’s latest Dupixent and Acoziborole milestones arrive as the shares trade at €82.2, with a 1 month share price return of 6.64% and a 1 day move of 1.63%. However, a 1 year total shareholder return...
ENXTPA:VIE
ENXTPA:VIEIntegrated Utilities

Assessing Veolia Environnement’s Valuation After Strong 2025 Results And New Contracts In India And The UK

Veolia Environnement (ENXTPA:VIE) is back in focus after reporting 2025 results that beat its EBITDA growth target, reached a record EBITDA margin, and paired this with a higher dividend and fresh 2026 guidance. See our latest analysis for Veolia Environnement. The strong 2025 earnings, higher dividend and new long term contracts in India and the UK have gone hand in hand with firm share price momentum, with a 30 day share price return of 13.94% and a 1 year total shareholder return of...
ENXTPA:BIM
ENXTPA:BIMMedical Equipment

Assessing bioMérieux (ENXTPA:BIM) Valuation After €4.1b Sales, Strong Cash Flow And SMARTBIOME Launch

bioMérieux (ENXTPA:BIM) just reported full year 2025 results, crossing €4.1b in sales with organic growth ahead of the market, cash flow up 40%, and SPOTFIRE and SMARTBIOME highlighting its diagnostics and food safety offering. See our latest analysis for bioMérieux. The full year results and SMARTBIOME launch appear to have given bioMérieux fresh momentum, with a 1 day share price return of 3.73% and a 7 day share price return of 4.99% at a €100.0 share price. Even so, the year to date share...
ENXTPA:VIRI
ENXTPA:VIRIEnergy Services

Assessing Viridien Société Anonyme (ENXTPA:VIRI) Valuation After Recent Share Price Pullback

Viridien Société anonyme (ENXTPA:VIRI) has drawn attention after recent share price moves, with the stock showing a 9.4% decline over the past day and an 8.8% drop across the past week. See our latest analysis for Viridien Société anonyme. That sharp 1-day share price return of negative 9.4% comes after a softer month, with a 30-day share price return of negative 13.9%. However, the longer backdrop is stronger, with a 1-year total shareholder return of 62.0% suggesting earlier optimism is now...
ENXTPA:VRLA
ENXTPA:VRLAPackaging

Verallia Net Zero 2040 Validation Meets Restructuring And Valuation Questions

SBTi has validated Verallia Société Anonyme's net zero 2040 ambition, confirming its greenhouse gas reduction trajectory. The company is restructuring its European operations, including site closures and capacity adjustments, in response to weak demand. These actions mark a shift in Verallia's long term plan and positioning within the glass packaging sector. The developments affect ENXTPA:VRLA and may influence how investors think about the balance between sustainability and industrial...
ENXTPA:AKE
ENXTPA:AKEChemicals

Arkema (ENXTPA:AKE) Margin Squeeze To 0.7% Tests Bullish Profitability Narratives

Arkema FY 2025 Results: Margins In Focus After Soft Q4 Arkema (ENXTPA:AKE) has wrapped up FY 2025 with fourth quarter revenue of €2.1b, a basic EPS loss of €0.26 and net income loss of €68m, while trailing twelve month revenue sits at €9.1b with EPS of €0.52 and net income of €63m. Over recent quarters the company has seen quarterly revenue move from €2.4b in Q1 2025 to €2.1b in Q4 2025, with EPS shifting from €0.65 in Q1 to a loss of €0.26 in Q4. This compares with a trailing net profit...
ENXTPA:IPS
ENXTPA:IPSMedia

Assessing Ipsos (ENXTPA:IPS) Valuation After Mixed Recent Share Performance

Recent share performance and context Ipsos (ENXTPA:IPS) has seen mixed share performance recently, with a 2.2% decline over the past day, a 10.9% gain over the past week, and a 3.7% decline over the past month. See our latest analysis for Ipsos. At a share price of €34.46, Ipsos has seen momentum fluctuate, with a 7.4% 90 day share price return set against a 25.0% decline in 1 year total shareholder return, pointing to shorter term strength after a tougher period. If this shift in sentiment...
ENXTPA:DEC
ENXTPA:DECMedia

Assessing JCDecaux (ENXTPA:DEC) Valuation After Global Rollout Of Its 360 Footprint Tool

Why JCDecaux’s 360 Footprint rollout matters for the stock JCDecaux (ENXTPA:DEC) is attracting fresh attention after extending its 360 Footprint measurement tool worldwide, connecting its outdoor advertising network more closely with environmental, social and economic impact reporting for client campaigns. See our latest analysis for JCDecaux. The 1 year total shareholder return of 24.6% contrasts with a 3 year total shareholder return decline of 20.1%. The recent 90 day share price return of...
ENXTPA:RNO
ENXTPA:RNOAuto

Renault Deepens EV Bet With Battery Push And Full Flexis Control

Renault's Ampere division has agreed a joint development plan with Basquevolt to work on next generation lithium metal batteries for future electric vehicles. Renault Group is acquiring full ownership of Flexis, reshaping its electric van joint venture previously shared with Volvo Group and CMA-CGM. Renault (ENXTPA:RNO) is trading at €32.11, with the share price showing a 32.4% decline over the past year and an 11.7% decline year to date. Over three and five years, returns of 18.3% and 8.6%...
ENXTPA:FDJU
ENXTPA:FDJUHospitality

FDJ United Leadership Changes Put Focus On Integration And Valuation Gap

FDJ United has reshaped its executive committee, appointing a new Chief Online Betting and Gaming Officer. An incoming General Secretary has been named while a key leader involved in integration work has resigned. The company has also flagged an upcoming appointment to the Chief Financial Officer role. For investors watching ENXTPA:FDJU, these leadership moves arrive at a time when the stock trades at €25.66 and has returned 12.8% over the past 30 days and 10.1% year to date. Over a longer...
ENXTPA:BB
ENXTPA:BBCommercial Services

Assessing Société BIC (ENXTPA:BB) Valuation After Dividend Reset And Portfolio Streamlining

Société BIC (ENXTPA:BB) has cut its ordinary dividend for fiscal 2025 to €2.40 per share, down from the total €3.08 per share distributed in June 2025, as it reshapes its portfolio. See our latest analysis for Société BIC. The 1 day share price return of 2.45% to €54.40 comes after a tougher recent spell, with a 7 day share price return of 5.72% and a 1 year total shareholder return of 2.76%, suggesting momentum has cooled after stronger gains over five years. If this dividend reset has you...
ENXTPA:TEP
ENXTPA:TEPProfessional Services

Teleperformance (ENXTPA:TEP) Margins Edge Down To 4.9% And Challenge Bullish Narratives

Teleperformance (ENXTPA:TEP) has reported its FY 2025 results with first half revenue of €5.1b and basic EPS of €4.22, while trailing twelve month figures show revenue of about €10.2b and EPS of €8.47. This gives investors a clear view of the group’s recent earnings power. Over recent periods the company has reported revenue of €5.08b and EPS of €4.85 in the first half of 2024, followed by revenue of €5.20b and EPS of €3.90 in the second half of 2024, before arriving at the latest half year...
ENXTPA:CS
ENXTPA:CSInsurance

AXA Earnings Growth And New Buyback Put Capital Returns In Focus

AXA (ENXTPA:CS) reported strong full year 2025 earnings growth. The company announced the start of an annual share buyback program, subject to shareholder approval. Management reiterated confidence in AXA's existing plan for the business alongside these capital actions. For investors watching AXA at a share price of €41.46, the combination of solid earnings in 2025 and a proposed recurring buyback program puts fresh attention on the insurer's capital allocation choices. The stock has...
ENXTPA:AM
ENXTPA:AMAerospace & Defense

Dassault Aviation Weighs New Private Jet Growth Paths In Tech And Sustainability

Market reports highlight accelerating growth in private aviation linked to technology and sustainability trends. Dassault Aviation société anonyme, listed as ENXTPA:AM, is referenced as a key player in business jets and advanced aircraft. New opportunities include electric and hybrid aircraft concepts and an expanding luxury travel ecosystem. Dassault Aviation société anonyme, through its Falcon business jets and defense activities, sits at the center of a private aircraft sector that is...
ENXTPA:VIRP
ENXTPA:VIRPPharmaceuticals

Is Virbac’s HABRI Partnership Subtly Reframing Its Human–Animal Health Narrative for Investors (ENXTPA:VIRP)?

The Human Animal Bond Research Institute (HABRI) recently announced a new partnership with Virbac to advance science-based education and outreach on the health benefits of the human-animal bond for pets and people. This collaboration ties Virbac’s animal health expertise to growing scientific evidence that pet ownership supports physical function, mobility and overall well-being in humans. We’ll now examine how this HABRI partnership, with its emphasis on science-backed education around the...
ENXTPA:SOP
ENXTPA:SOPIT

Assessing Sopra Steria Group (ENXTPA:SOP) Valuation After Profit Growth And Higher Dividend Proposal

Sopra Steria Group (ENXTPA:SOP) is back in focus after reporting an 18.3% rise in 2025 net profit, a return to organic revenue growth in Q4, and proposing a higher €5.30 per share dividend. See our latest analysis for Sopra Steria Group. The 1-day share price return of 1.16% and 7-day gain of 8.16% have come after management approved the 2025 results, announced the planned €5.30 dividend, and outlined further expansion in defence, aeronautics, public sector and AI. However, the year to date...
ENXTPA:TE
ENXTPA:TEEnergy Services

Technip Energies (ENXTPA:TE) Margin Decline To 5.1% Challenges Bullish Profitability Narratives

Technip Energies (ENXTPA:TE) has wrapped up FY 2025 with fourth quarter revenue of €1.8b and basic EPS of €0.48, capping a twelve month stretch where trailing revenue came in at €7.2b and basic EPS at €2.04. The company has seen quarterly revenue move between €1.74b and €1.94b since late 2024, while basic EPS has ranged from €0.47 to €0.70 over the same period, giving investors a clear view of how top line scale and per share earnings have tracked through the year. With net profit margins...
ENXTPA:AMUN
ENXTPA:AMUNCapital Markets

Is It Too Late To Consider Amundi (ENXTPA:AMUN) After Its Strong Recent Share Price Run?

If you are wondering whether Amundi is priced attractively today, this article walks through what the current share price might be implying about its underlying value. With the stock at €81.05 and returns of 2.2% over 7 days, 8.6% over 30 days, 13.8% year to date, 25.0% over 1 year, 55.5% over 3 years and 70.3% over 5 years, many investors are asking whether the recent performance still leaves room for a reasonable entry point. Recent news around Amundi has kept attention on how large asset...
ENXTPA:KER
ENXTPA:KERLuxury

Is Kering (ENXTPA:KER) Pricing In Too Much Optimism After Recent Share Price Rebound

If you are wondering whether Kering is attractively priced right now, this article will walk through what the current share price might be implying about its value. The stock recently closed at €285.90, with returns of 2.8% over the last 7 days and 7.4% over the last 30 days. The year to date return stands at a 6.1% decline and the 1 year return at 8.2%, after a 45.7% decline over 3 years and a 39.5% decline over 5 years. These moves sit against ongoing discussion around how luxury spending...
ENXTPA:LI
ENXTPA:LIRetail REITs

A Look At Klépierre’s (ENXTPA:LI) Valuation After Strong 2025 Results And A Higher Proposed Dividend

Klépierre (ENXTPA:LI) has drawn fresh interest after reporting full year 2025 earnings and proposing a higher cash dividend, alongside several supervisory board changes that reshape the company’s governance backdrop. See our latest analysis for Klépierre. Those full year 2025 results and the 3% higher proposed dividend appear to sit behind recent share price momentum, with a 9.0% 1 month share price return and a 23.0% 1 year total shareholder return pointing to building confidence rather than...
ENXTPA:VIE
ENXTPA:VIEIntegrated Utilities

Veolia Environnement (ENXTPA:VIE) Margin Improvement Tests Bearish Leverage Concerns

Veolia Environnement (ENXTPA:VIE) FY 2025 Results Snapshot Veolia Environnement (ENXTPA:VIE) has reported FY 2025 first half revenue of €22.0b and basic EPS of €0.91, with trailing 12 month EPS of €1.70 on revenue of €44.4b framing the latest set of numbers. The company has seen revenue move from €44.7b to €44.4b on a trailing 12 month basis, while EPS has shifted from €1.47 to €1.70 over the same window. This sets up the current release against an 11.2% earnings growth profile and a net...
ENXTPA:SU
ENXTPA:SUElectrical

Schneider Electric (ENXTPA:SU) Margin Compression Challenges Bullish Growth Narratives

Schneider Electric (ENXTPA:SU) has released its FY 2025 numbers, reporting second half revenue of €20.8b and basic EPS of €3.99, alongside trailing 12 month revenue of €40.2b and EPS of €7.41. These figures frame the latest results against a fuller year of performance. The company’s revenue increased from €19.98b in the second half of 2024 to €20.8b in the second half of 2025, while basic EPS moved from €4.25 to €3.99 over the same periods. This sets up a results season in which investors are...
ENXTPA:IPN
ENXTPA:IPNPharmaceuticals

Ipsen (ENXTPA:IPN) Valuation Check As Rare Disease Manufacturing Partnership With Quotient Sciences Expands

Quotient Sciences partnership extension and rare disease focus Ipsen (ENXTPA:IPN) is back in focus after extending its commercial supply partnership with Quotient Sciences to manufacture therapy for Fibrodysplasia Ossificans Progressiva, an ultra rare condition with highly specific treatment needs. The move includes Ipsen funding new equipment at Quotient Sciences' Boothwyn facility, aimed at handling highly potent compounds such as Sohonos and supporting commercial scale supply of multiple...